These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 25609248)
1. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Wong AL; Soo RA; Tan DS; Lee SC; Lim JS; Marban PC; Kong LR; Lee YJ; Wang LZ; Thuya WL; Soong R; Yee MQ; Chin TM; Cordero MT; Asuncion BR; Pang B; Pervaiz S; Hirpara JL; Sinha A; Xu WW; Yuasa M; Tsunoda T; Motoyama M; Yamauchi T; Goh BC Ann Oncol; 2015 May; 26(5):998-1005. PubMed ID: 25609248 [TBL] [Abstract][Full Text] [Related]
2. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. Ogura M; Uchida T; Terui Y; Hayakawa F; Kobayashi Y; Taniwaki M; Takamatsu Y; Naoe T; Tobinai K; Munakata W; Yamauchi T; Kageyama A; Yuasa M; Motoyama M; Tsunoda T; Hatake K Cancer Sci; 2015 Jul; 106(7):896-901. PubMed ID: 25912076 [TBL] [Abstract][Full Text] [Related]
3. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Jänne PA; Boss DS; Camidge DR; Britten CD; Engelman JA; Garon EB; Guo F; Wong S; Liang J; Letrent S; Millham R; Taylor I; Eckhardt SG; Schellens JH Clin Cancer Res; 2011 Mar; 17(5):1131-9. PubMed ID: 21220471 [TBL] [Abstract][Full Text] [Related]
4. Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. Yoo C; Kang J; Lim HY; Kim JH; Lee MA; Lee KH; Kim TY; Ryoo BY Cancer Res Treat; 2019 Apr; 51(2):510-518. PubMed ID: 29898591 [TBL] [Abstract][Full Text] [Related]
5. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Bendell JC; Hong DS; Burris HA; Naing A; Jones SF; Falchook G; Bricmont P; Elekes A; Rock EP; Kurzrock R Cancer Chemother Pharmacol; 2014 Jul; 74(1):125-30. PubMed ID: 24819685 [TBL] [Abstract][Full Text] [Related]
6. Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. Oh DY; Lee SH; Han SW; Kim MJ; Kim TM; Kim TY; Heo DS; Yuasa M; Yanagihara Y; Bang YJ Cancer Res Treat; 2015 Oct; 47(4):607-15. PubMed ID: 25715763 [TBL] [Abstract][Full Text] [Related]
7. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations. Nishio M; Murakami H; Ohe Y; Hida T; Sakai H; Kasahara K; Imamura F; Baba T; Kubota K; Hosomi Y; Shimokawa T; Hayashi H; Miyadera K; Tamura T Invest New Drugs; 2019 Dec; 37(6):1207-1217. PubMed ID: 30790152 [TBL] [Abstract][Full Text] [Related]
8. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822 [TBL] [Abstract][Full Text] [Related]
9. A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification. Angevin E; Spitaleri G; Rodon J; Dotti K; Isambert N; Salvagni S; Moreno V; Assadourian S; Gomez C; Harnois M; Hollebecque A; Azaro A; Hervieu A; Rihawi K; De Marinis F Eur J Cancer; 2017 Dec; 87():131-139. PubMed ID: 29145039 [TBL] [Abstract][Full Text] [Related]
10. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Shapiro GI; Rodon J; Bedell C; Kwak EL; Baselga J; Braña I; Pandya SS; Scheffold C; Laird AD; Nguyen LT; Xu Y; Egile C; Edelman G Clin Cancer Res; 2014 Jan; 20(1):233-45. PubMed ID: 24166903 [TBL] [Abstract][Full Text] [Related]
11. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201 [TBL] [Abstract][Full Text] [Related]
12. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors. Li T; LoRusso P; Maitland ML; Ou SH; Bahceci E; Ball HA; Park JW; Yuen G; Tolcher A J Hematol Oncol; 2016 Mar; 9():23. PubMed ID: 26966027 [TBL] [Abstract][Full Text] [Related]
13. Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. Macaulay VM; Middleton MR; Eckhardt SG; Rudin CM; Juergens RA; Gedrich R; Gogov S; McCarthy S; Poondru S; Stephens AW; Gadgeel SM Clin Cancer Res; 2016 Jun; 22(12):2897-907. PubMed ID: 26831715 [TBL] [Abstract][Full Text] [Related]
14. Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase. Isambert N; Delord JP; Soria JC; Hollebecque A; Gomez-Roca C; Purcea D; Rouits E; Belli R; Fumoleau P Ann Oncol; 2015 May; 26(5):1005-1011. PubMed ID: 25646368 [TBL] [Abstract][Full Text] [Related]
15. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570 [TBL] [Abstract][Full Text] [Related]
16. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Jones RL; Kim ES; Nava-Parada P; Alam S; Johnson FM; Stephens AW; Simantov R; Poondru S; Gedrich R; Lippman SM; Kaye SB; Carden CP Clin Cancer Res; 2015 Feb; 21(4):693-700. PubMed ID: 25208878 [TBL] [Abstract][Full Text] [Related]
17. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613 [TBL] [Abstract][Full Text] [Related]
18. Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. Kim TM; Lee KW; Oh DY; Lee JS; Im SA; Kim DW; Han SW; Kim YJ; Kim TY; Kim JH; Han H; Kim WH; Bang YJ Cancer Res Treat; 2018 Jul; 50(3):835-842. PubMed ID: 28859471 [TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies. Hammond-Thelin LA; Thomas MB; Iwasaki M; Abbruzzese JL; Lassere Y; Meyers CA; Hoff P; de Bono J; Norris J; Matsushita H; Mita A; Rowinsky EK Invest New Drugs; 2012 Feb; 30(1):316-26. PubMed ID: 20839029 [TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results. Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]